Linda Marbán

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.  CAPR stock is soaring. See the real-time price action here.  The data release and stock...

Even as it recovered from poor fourth-quarter results, Capricor Therapeutics Inc (NASDAQ: CAPR) pumped a little hope into the world of Duchenne muscular dystrophy last week with positive clinical results from its CAP-1002 study. And the breadth of impact could ultimately be more expansive. “...